GlassScriptPhysician profile
Prakash N Roy
NPI 1992754808
$11,413.39
in general payments reported to CMS, 2019-2025
40 companies · $2,932 in 2025
The $2,932 reported for 2025 was more than what 92% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $724 · 2020: $171 · 2021: $1,046 · 2022: $1,765 · 2023: $1,967 · 2024: $2,810 · 2025: $2,932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,606 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,606.41 |
| Education | $101.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,602.20 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $1,348.12 | 2021-2025 | |
| Calliditas Therapeutics US INC. | $812.75 | 2022-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $660.87 | 2021-2025 | Lupkynis |
| Amgen INC. | $640.14 | 2022-2025 | Krystexxa, Tavneos, Uplizna |
| Otsuka America Pharmaceutical, INC. | $603.56 | 2019-2025 | Jynarque, Voyxact |
| Vifor Pharma, INC. | $585.47 | 2019-2025 | Veltassa, Korsuva |
| Opko Pharmaceuticals, LLC | $568.70 | 2020-2025 | Rayaldee |
| Novo Nordisk INC | $525.44 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $475.97 | 2022-2025 | |
| Ardelyx, INC. | $411.89 | 2024-2025 | Ibsrela, Xphozah 30 Mg |
| Travere Therapeutics, INC. | $372.23 | 2022-2025 | |
| Daiichi Sankyo INC. | $331.67 | 2020-2024 | Injectafer |
| Horizon Therapeutics Plc | $256.74 | 2021-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $232.79 | 2021-2024 | Arexvy, Benlysta |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nxstage Medical, INC. | $184.07 | 2019-2025 | Pureflow Sl, Liberty Select Cycler, Nxstage System One |
| Akebia Therapeutics INC | $151.52 | 2019-2025 | Vafseo, Auryxia |
| Bard Peripheral Vascular, INC. | $148.70 | 2019 | |
| Vantive US Healthcare LLC | $144.04 | 2025 | Renal - Pd |
| Mallinckrodt Hospital Products INC. | $136.15 | 2021-2025 | Terlivaz, Acthar |
| Takeda Pharmaceuticals U.S.A., INC. | $134.70 | 2021-2022 | |
| Fresenius USA Marketing, INC. | $127.07 | 2021-2024 | Velphoro |
| Janssen Pharmaceuticals, INC | $116.92 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.05 | 2022-2023 | Jardiance |
| Renalytix Ai, INC. | $105.95 | 2022-2024 | Kidneyintelx Blood Collection Convenience Kit |
| Ultragenyx Pharmaceutical INC. | $86.17 | 2021-2024 | Crysvita |
| Kyowa Kirin, INC. | $82.26 | 2024-2025 | Crysvita |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $72.34 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $69.22 | 2019 | |
| Alexion Pharmaceuticals, INC. | $62.35 | 2021-2023 | |
| Baxter Healthcare | $42.19 | 2019 | |
| Scpharmaceuticals INC. | $40.02 | 2025 | |
| Biomerieux INC | $27.27 | 2024 | Vidas Nephrocheck |
| Lilly USA, LLC | $25.02 | 2024 | Jardiance |
| Ani Pharmaceuticals, INC. | $23.50 | 2024 | Purified Cortrophin Gel |
| Sanofi-Aventis U.S. LLC | $21.06 | 2021 | |
| Cycle Pharmaceuticals INC | $20.38 | 2025 | Venxxiva |
| Gilead Sciences, INC. | $17.26 | 2023 | |
| Mallinckrodt Enterprises LLC | $17.23 | 2019 | |
| Apellis Pharmaceuticals, INC. | $15.41 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prakash Roy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.